Filing Flows › Cue Biopharma (CUE) › Q1 2025
Cue Biopharma (CUE) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Cue Biopharma (CUE) reported revenue of $421K for the first quarter 2025 (Q1 2025), -75% from a year earlier and -73% from the quarter before.
Cue Biopharma, Q1 2025: revenue $421K (-76% year over year), net loss $12.3M, operating cash flow −$8.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $421K | -73% | -75% |
| Operating profit | −$12.3M | — | — |
| Net earnings | −$12.3M | — | — |
| Operating cash flow | −$8.2M | — | — |
What changed
Revenue was $421K in Q1 2025, down 75% year over year and down 73% from the previous quarter.
Operating costs exceeded revenue by $12.3M, an operating margin of -2921.4%. Total costs fell 12% while revenue fell 75%. The quarter ended with a net loss of $12.3M, wider than the previous quarter's $9.5M loss.
Operating cash flow was −$8.2M. Non-cash charges added back $101K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $2.6M. Capital expenditures of $150K exceeded it, leaving free cash flow of −$8.3M.
Questions
What was Cue Biopharma's revenue in the first quarter 2025?
Cue Biopharma (CUE) reported revenue of $421K for the first quarter 2025 (Q1 2025), -75% from a year earlier and -73% from the quarter before.
Source: Cue Biopharma 10-Q on SEC EDGAR.